Hedeker Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Hedeker Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.73M	Sell	7,515 -111	-1%	-$49.2K	0.71%	42
2026 Q1	$3.41M	Buy	7,626 +2,961	+63%	+$1.38M	0.72%	42
2025 Q4	$2.11M	Sell	4,665 -2,996	-39%	-$1.29M	0.44%	54
2025 Q3	$3M	Sell	7,661 -1,130	-13%	-$472K	0.62%	46
2025 Q2	$3.91M	Sell	8,791 -216	-2%	-$99.5K	0.91%	37
2025 Q1	$4.37M	Buy	+9,007	New	+$4.2M	1.17%	31
2021 Q3	–	Sell	-8,717	Closed	-$1.76M	–	94
2021 Q2	$1.76M	Buy	8,717 +122	+1%	+$25.5K	0.55%	60
2021 Q1	$1.85M	Buy	8,595 +202	+2%	+$44.4K	0.65%	55
2020 Q4	$1.98M	Buy	8,393 +706	+9%	+$162K	0.69%	55
2020 Q3	$2.09M	Buy	+7,687	New	+$2.12M	0.99%	45

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Hedeker Wealth's VRTX Position: Q2 2026 in Review

Hedeker Wealth reduced its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q2 2026, selling an estimated $49.2K and leaving 7,515 shares worth $3.73M. The position accounts for 0.71% of the portfolio, ranked #42.

Hedeker Wealth first reported a position in VRTX in Q3 2020 and has held it in 10 quarters since. The position peaked at $4.37M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Hedeker Wealth held 7,515 shares of Vertex Pharmaceuticals worth $3.73M as of Q2 2026.
Hedeker Wealth sold 111 Vertex Pharmaceuticals shares in Q2 2026, an estimated $49.2K.
Vertex Pharmaceuticals made up 0.71% of Hedeker Wealth's portfolio in Q2 2026, its #42 holding.
Hedeker Wealth first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 10 quarters since.
Hedeker Wealth's Vertex Pharmaceuticals position peaked at $4.37M in Q1 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Hedeker Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.